Novo Nordisk, the maker of Wegovy and Ozempic, gave investors good news. It raised its full-year guidance, and the shares climbed 5.6%. The reason is a new weight-loss pill that's selling faster than expected. Third-quarter sales rose 6% and adjusted operating profit jumped 34%, both beating forecasts. But underneath the good quarter is a clock every drug company lives by.
First the good part. The new pill reached 5.39 billion Danish kroner, about $807 million, in quarterly sales, well above the 4.5 billion expected. A pill is easier to take than an injection, and Novo has rolled it out in the U.S., U.K., Germany and more, with over 20 markets planned for 2027. That early lead in the pill version of weight-loss drugs is why the stock rose.
The clock underneath
Now the clock. Novo faces two pressures at once. Eli Lilly's rival shot has been eating into Novo's share of the injectable market. And patent protection on the key ingredient in Wegovy and Ozempic has already expired in some countries, including India, Canada and Brazil, with more to follow. When a patent expires, cheaper generic copies can enter and prices fall. Every blockbuster drug faces this eventually. It's called the patent cliff, and it's why a drugmaker that stops launching new products slowly fades even if today's sales look great. Novo's pill is its answer to the cliff on its older drugs.
We hold Novo in 11 of our model books and Eli Lilly, its chief rival, in 23. Our model books changed little this week: a CoreWeave trim and two small swaps, nothing in the North Star. Owning both sides of a close race is one way to hold a theme without betting the outcome.
Our read
This is an Investments and Risk story, module IN04, about how drug companies really work. A blockbuster drug isn't a permanent money machine. It's a clock. The patent runs for a set time, and when it ends, generics arrive and the river of profit dries up. The whole game is launching the next blockbuster before the last one's clock runs out. Novo's pill is that next launch, racing the expiring patents on its older drugs.
For an investor, this has one clear lesson: don't fall in love with a single company on the strength of one hit product. The company behind today's miracle drug could face a patent cliff and a fierce rival at the same time, which is exactly Novo's situation. The safer way to own a trend as big as weight-loss drugs is to own more than one runner. Or own it inside a broad health-care fund that holds the whole field. That way a patent cliff at one company is offset by a launch at another. We hold both Novo and Eli Lilly for this reason. Here's the check this week. If you own a single drug or biotech stock, ask when its main product loses patent protection and what's behind it in the pipeline. If you can't answer, you're trusting a clock you can't see. If you'd like help thinking about how to own a health-care theme without a single-company bet, that's fifteen minutes.